
Erin E Salo-Mullen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6990268/publications.pdf Version: 2024-02-01



FRIN F SALO-MULLEN

#	Article	IF	CITATIONS
1	Factors Influencing Patient Preferences for Telehealth Cancer Genetic Counseling During the COVID-19 Pandemic. JCO Oncology Practice, 2022, 18, e462-e471.	2.9	8
2	Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 362-371.	2.5	7
3	Early age of onset and broad cancer spectrum persist in MSH6- and PMS2-associated Lynch syndrome. Genetics in Medicine, 2022, 24, 1187-1195.	2.4	7
4	Resolving pathogenicity classification for the CDH1 c.[715G>A] (p.Gly239Arg) Variant. European Journal of Human Genetics, 2021, 29, 1103-1109.	2.8	1
5	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. Nature Cancer, 2021, 2, 357-365.	13.2	74
6	Prevalence and Characterization of Biallelic and Monoallelic <i>NTHL1</i> and <i>MSH3</i> Variant Carriers From a Pan-Cancer Patient Population. JCO Precision Oncology, 2021, 5, 455-465.	3.0	10
7	Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes. Journal of the National Cancer Institute, 2021, 113, 1194-1202.	6.3	35
8	Insertion of an <scp>SVA</scp> element in <scp><i>MSH2</i></scp> as a novel cause of Lynch syndrome. Genes Chromosomes and Cancer, 2021, 60, 571-576.	2.8	6
9	Disparities in pan-cancer patients undergoing germline cancer risk assessment by self-reported race/ethnicity and ancestry Journal of Clinical Oncology, 2021, 39, 10508-10508.	1.6	2
10	Paired Tumor-Normal Sequencing Provides Insights into TP53-Related Cancer Spectrum in Li-Fraumeni Patients. Journal of the National Cancer Institute, 2021, , .	6.3	6
11	Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer. Genetics in Medicine, 2021, 23, 2105-2113.	2.4	29
12	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. Journal of the National Cancer Institute, 2021, 113, 1683-1692.	6.3	66
13	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. Journal of Clinical Oncology, 2021, 39, 2698-2709.	1.6	83
14	Pancreas cancer and <i>BRCA</i> : A critical subset of patients with improving therapeutic outcomes. Cancer, 2021, 127, 4393-4402.	4.1	24
15	Genetic Factors. , 2020, , 180-208.e11.		4
16	Insertion of an Aluâ€like element in <i>MLH1</i> intron 7 as a novel cause of Lynch syndrome. Molecular Genetics & Genomic Medicine, 2020, 8, e1523.	1.2	4
17	Mismatch Repair–Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. Clinical Cancer Research, 2020, 26, 3271-3279.	7.0	118
18	Risk of Metachronous Colorectal Neoplasm after a Segmental Colectomy in Lynch Syndrome Patients According to Mismatch Repair Gene Status. Journal of the American College of Surgeons, 2020, 230, 669-675.	0.5	16

ERIN E SALO-MULLEN

#	Article	IF	CITATIONS
19	An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice. JAMA Oncology, 2020, 6, 764.	7.1	35
20	Indications for Total Gastrectomy in <i>CDH1</i> Mutation Carriers and Outcomes of Risk-Reducing Minimally Invasive and Open Gastrectomies. JAMA Surgery, 2020, 155, 1050.	4.3	34
21	Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in <i>BRCA1</i> and <i>BRCA2</i> . Cancer Prevention Research, 2019, 12, 599-608.	1.5	6
22	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. Journal of the National Cancer Institute, 2018, 110, 1067-1074.	6.3	170
23	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Clinical Cancer Research, 2018, 24, 1326-1336.	7.0	281
24	Contiguous gene deletion of chromosome 2p16.3-p21 as a cause of Lynch syndrome. Familial Cancer, 2018, 17, 71-77.	1.9	10
25	Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. European Journal of Cancer, 2018, 89, 19-26.	2.8	125
26	Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer. Breast Cancer Research and Treatment, 2017, 162, 297-306.	2.5	16
27	Educational and Psychosocial Support Needs in Lynch Syndrome: Implementation and Assessment of an Educational Workshop and Support Group. Journal of Genetic Counseling, 2017, 26, 232-243.	1.6	14
28	CDH1 Missense Variant c.1679C>G (p.T560R) Completely Disrupts Normal Splicing through Creation of a Novel 5' Splice Site. PLoS ONE, 2016, 11, e0165654.	2.5	16
29	Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1-13.	3.0	39
30	Genome Sequencing of Multiple Primary Tumors Reveals a Novel <i>PALB2</i> Variant. Journal of Clinical Oncology, 2016, 34, e61-e67.	1.6	6
31	Identification of germline genetic mutations in patients with pancreatic cancer. Cancer, 2015, 121, 4382-4388.	4.1	167
32	Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families. Breast Cancer Research and Treatment, 2014, 145, 625-634.	2.5	11
33	Mosaic partial deletion of the PTEN gene in a patient with Cowden syndrome. Familial Cancer, 2014, 13, 459-467.	1.9	14
34	Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC) Journal of Clinical Oncology, 2014, 32, 4023-4023.	1.6	17
35	Variable penetrance of CDH1 mutation diffuse gastric cancer: A genomic analysis Journal of Clinical Oncology, 2013, 31, 4082-4082.	1.6	0
36	Juvenile Polyposis Syndrome Presenting With Familial Gastric Cancer and Massive Gastric Polyposis. Journal of Clinical Oncology, 2012, 30, e229-e232.	1.6	9

#	Article	IF	CITATIONS
37	The Prevalence of Thyroid Cancer and Benign Thyroid Disease in Patients With Familial Adenomatous Polyposis May Be Higher Than Previously Recognized. Clinical Colorectal Cancer, 2012, 11, 304-308.	2.3	52
38	The Genetic Counselor. Advances in Surgery, 2012, 46, 137-153.	1.3	2
39	Systematic Immunohistochemistry Screening for Lynch Syndrome in Early Age-of-Onset Colorectal Cancer Patients Undergoing Surgical Resection. Journal of the American College of Surgeons, 2012, 214, 61-67.	0.5	32
40	Prevalence of <i>BRCA1</i> and <i>BRCA2</i> mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer, 2012, 118, 493-499.	4.1	83
41	Germline PALB2 mutation analysis in breast-pancreas cancer families. Journal of Medical Genetics, 2011, 48, 523-525.	3.2	28
42	An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known <i>BRCA</i> Mutation: Clinical Descriptors, Treatment Implications, and Future Directions. Oncologist, 2011, 16, 1397-1402.	3.7	227